ArticleHealthcare (Basel, Switzerland)2018
The Financial Implications of a Well-Hidden and Ignored Chronic Lyme Disease Pandemic.
Article in Healthcare (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Patient roadmap and economic burden of chronic tick-borne illness and post-treatment Lyme disease syndrome in Ireland, and public health issues arising.Frontiers in public health · 2026Article
- Serologic biomarker discovery for differentiating Lyme disease from diseases with similar clinical symptoms using broad profiling of antibody binding.Frontiers in immunology · 2025Article
- Scrutinizing Clinical Biomarkers in a Large Cohort of Patients with Lyme Disease and Other Tick-Borne Infections.Microorganisms · 2024Article
- Leveraging machine learning approaches for predicting potential Lyme disease cases and incidence rates in the United States using Twitter.BMC medical informatics and decision making · 2023Article
- Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.Frontiers in immunology · 2022Article
- Monitoring Risk: Tick andPathogens (Basel, Switzerland) · 2021Article
- The USDA-ARS Ag100Pest Initiative: High-Quality Genome Assemblies for Agricultural Pest Arthropod Research.Insects · 2021Article
- Article
- Assessing the Need for Multiplex and Multifunctional Tick-Borne Disease Test in Routine Clinical Laboratory Samples from Lyme Disease and Febrile Patients with a History of a Tick Bite.Tropical medicine and infectious disease · 2021Article
- Presentation of Acrodermatitis Chronica Atrophicans Rashes on Lyme Disease Patients in Canada.Healthcare (Basel, Switzerland) · 2020Article
- Lyme Disease: Diversity ofHealthcare (Basel, Switzerland) · 2020Article
- Monitoring of Nesting Songbirds Detects Established Population of Blacklegged Ticks and Associated Lyme Disease Endemic Area in Canada.Healthcare (Basel, Switzerland) · 2020Article
- What Are the Costs of Diagnostics and Treatment of Lyme Borreliosis in Poland?Frontiers in public health · 2020Article
- Detection and Transstadial Passage ofHealthcare (Basel, Switzerland) · 2019Article
- Differentiating Psychosomatic, Somatopsychic, Multisystem Illnesses, and Medical Uncertainty.Healthcare (Basel, Switzerland) · 2019Review
- Proposed Lyme Disease Guidelines and Psychiatric Illnesses.Healthcare (Basel, Switzerland) · 2019Review
- Malaria and Lyme disease - the largest vector-borne US epidemics in the last 100 years: success and failure of public health.BMC public health · 2019Article
- Evaluating polymicrobial immune responses in patients suffering from tick-borne diseases.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1 million people are predicted to get infected with Lyme disease in the USA in 2018. Given the same incidence rate of Lyme disease in Europe as in the USA, then 2.4 million people will get infected with Lyme disease in Europe in 2018. In the USA by 2050, 55.7 million people (12% of the population) will have been infected with Lyme disease. In Europe by 2050, 134.9 million people (17% of the population) will have been infected with Lyme disease. Most of these infections will, unfortunately, become chronic. The estimated treatment cost for acute and chronic Lyme disease for 2018 for the USA is somewhere between 4.8 billion USD and 9.6 billion USD and for Europe somewhere between 10.1 billion EUR and 20.1 billion EUR. If governments do not finance IV treatment with antibiotics for chronic Lyme disease, then the estimated government cost for chronic Lyme disease for 2018 for the USA is 10.1 billion USD and in Europe 20.1 billion EUR. If governments in the USA and Europe want to minimize future costs and maximize future revenues, then they should pay for IV antibiotic treatment up to a year even if the estimated cure rate is as low as 25%. The cost for governments of having chronic Lyme patients sick in perpetuity is very large.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.